MBX Biosciences Reports Director Departure, Officer Compensation
Ticker: MBX · Form: 8-K · Filed: Apr 7, 2025 · CIK: 1776111
Sentiment: neutral
Topics: director-departure, officer-compensation, filings
TL;DR
MBX Bio director out, officer pay details, and financials filed.
AI Summary
MBX Biosciences, Inc. announced on April 7, 2025, the departure of Director David E. Johnson. The company also reported on compensatory arrangements for its officers and provided a Regulation FD disclosure. Additionally, MBX Biosciences filed financial statements and exhibits as part of this 8-K filing.
Why It Matters
Changes in directorship and disclosures about officer compensation can signal shifts in company strategy or governance, impacting investor confidence.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance and disclosures, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- MBX Biosciences, Inc. (company) — Registrant
- David E. Johnson (person) — Departing Director
- April 07, 2025 (date) — Report Date
- 11711 N. Meridian Street Suite 300 (location) — Principal Executive Offices
- Carmel, Indiana (location) — Principal Executive Offices Location
FAQ
Who is the departing director and when did their departure become effective?
Director David E. Johnson departed, with the report date being April 07, 2025.
What are the main items reported in this 8-K filing?
The filing covers the departure of a director, election of directors, appointment of officers, compensatory arrangements of certain officers, Regulation FD disclosure, and financial statements and exhibits.
What is the exact address of MBX Biosciences' principal executive offices?
The principal executive offices are located at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032.
What is the company's Central Index Key (CIK)?
MBX Biosciences, Inc.'s Central Index Key is 0001776111.
What is the SEC file number for MBX Biosciences, Inc.?
The SEC file number for MBX Biosciences, Inc. is 001-42272.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 by David E. Johnson regarding MBX Biosciences, Inc. (MBX).